SEC Form 4 filed by Chief Executive Officer Lee-Sepsick Kathy

$FEMY
Medical/Dental Instruments
Health Care
Get the next $FEMY alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lee-Sepsick Kathy

(Last) (First) (Middle)
C/O FEMASYS INC.
3950 JOHNS CREEK COURT, SUITE 100

(Street)
SUWANEE GA 30024

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
FEMASYS INC [ FEMY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/29/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $1.17 01/29/2025 A 59,849 (1) 01/29/2035 Common Stock 59,849 $0 59,849 D
Stock Option (Right to Buy) $1.17 01/29/2025 A 120,353 01/29/2025 01/29/2035 Common Stock 120,353 $0 120,353 D
Stock Option (Right to Buy) $1.17 01/29/2025 A 262,700 (2) 01/29/2035 Common Stock 262,700 $0 262,700 D
Explanation of Responses:
1. The shares underlying the stock option vest equally in installments over 3 years beginning on January 29, 2025, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date.
2. The shares underlying the stock option vest equally in installments over 4 years beginning on January 29, 2025, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date.
/s/ Kathy Lee-Sepsick 01/30/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $FEMY alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FEMY

DatePrice TargetRatingAnalyst
7/13/2021$18.00Buy
JonesTrading
7/13/2021$25.00Buy
Chardan Capital
More analyst ratings

$FEMY
Press Releases

Fastest customizable press release news feed in the world

See more
  • Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

    -- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the year ended December 31, 2024 and provides a corporate update. Corporate Highlights from 4Q 2024 to date Announced FemBloc® permanent birth control (delivery system) approval in Europe; FemBloc blended polymer component s

    $FEMY
    Medical/Dental Instruments
    Health Care
  • Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

    ATLANTA, March 19, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces a partnership with CNY Fertility, a national provider of fertility services across the U.S. CNY Fertility will provide the Company's FemaSeed intratubal insemination product as an infertility treatment option to patients throughout its network of 11 locations. "We are thrilled to partner with CNY Fertility, a prominent infertility group, to continue to expand access of our FemaSeed infertility treatment to those seeki

    $FEMY
    Medical/Dental Instruments
    Health Care
  • Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

    -- Company taps first EU distributors, Comercial Medico Quirurigca, SA and Durgalab, as the first globally to be granted rights to commercialize FemBloc® -- ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces the Company has secured strategic distribution partnerships for FemBloc® in Spain. Comercial Medico Quirurigca, SA (CMQ) will expand its commercial portfolio to include FemBloc, alongside other Femasys products in northern Spain, while Durgalab will handle distribu

    $FEMY
    Medical/Dental Instruments
    Health Care

$FEMY
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$FEMY
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$FEMY
SEC Filings

See more

$FEMY
Leadership Updates

Live Leadership Updates

See more
  • Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

    ATLANTA, March 21, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing the significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, invites investors to join management in a Fireside Chat with Jones Trading Analyst Catherine Novack to discuss the current treatment landscape for infertility treatment in women. Those interested in attending the event, which will be held virtually TODAY, March 21, 2024 at 1PM ET, may register here. Femasys CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu, M.D. will focus on the current treatment options in the inf

    $FEMY
    Medical/Dental Instruments
    Health Care
  • Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

    -- Seasoned sales and marketing executive with 25 years of experience leading public and private healthcare companies throughout various stages of commercialization will lead commercial launch of FemaSeed -- ATLANTA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the appointment of Richard Spector to chief commercial officer (CCO), effective February 2024. Mr. Spector has 25 years of experience spanning a contin

    $FEMY
    Medical/Dental Instruments
    Health Care
  • Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

    ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the appointment of James Liu, M.D., as Chief Medical Officer. Dr. Liu joins Femasys as the company accelerates commercialization of its product pipeline, including a new therapeutic for artificial insemination, FemaSeed®. "With an exciting product pipeline and a culture focused on execution of the development and commercialization of differentiated women's

    $FEMY
    Medical/Dental Instruments
    Health Care

$FEMY
Financials

Live finance-specific insights

See more
  • Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

    -- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the year ended December 31, 2024 and provides a corporate update. Corporate Highlights from 4Q 2024 to date Announced FemBloc® permanent birth control (delivery system) approval in Europe; FemBloc blended polymer component s

    $FEMY
    Medical/Dental Instruments
    Health Care
  • Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

    ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended September 30, 2024 and provides a corporate update. Corporate Highlights from 3Q 2024 to date Announced partnership with Boston IVF, prominent network of fertility centers, to offer FemaSeed®Announced the onboarding of the first infertility medical clinic customers to offer FemaSeed infertility treatment to patients in California and FloridaAnnounced strategic distributi

    $FEMY
    Medical/Dental Instruments
    Health Care
  • Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

    ATLANTA, Aug. 08, 2024 (GLOBE NEWSWIRE) --  Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended June 30, 2024 and provides a corporate update. Corporate Highlights from 2Q 2024 to date Company received European Union Medical Device Regulation (EU MDR) certification and CE Mark for four of its women's health products, providing regulatory approval to begin marketing in the European Union. Further, it serves as independent validation of F

    $FEMY
    Medical/Dental Instruments
    Health Care

$FEMY
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more